Glaucoma patients taking topical medication have more ocular surface disease than non-glaucoma patients.
A study of over 200 eyes using topical glaucoma medication gauged the level of ocular surface disease by using four outcomes measures: TBUT, corneal staining, tear meniscus height, and the OSD symptom questionnaire index (OSDI). Fifty-one control eyes were used for comparison.
The conclusion: Ocular surface disease was more prevalent in the eyes taking topical glaucoma medications. The main factors impacting OSD were drops with preservatives, longer treatment duration, and older age. (via)
You probably don’t need a study to tell you this but here you go.
